Abstract：
While immunomodulatory imide drugs (IMiDs) have been authorised for treatment of haematological cancers for over two decades, the appreciation of their ability to stimulate antitumour T cell and natural killer (NK) cell responses is relatively recent. Clinical trial data increasingly show that targeted immunotherapies, such as antibodies, T cells, and vaccines, improve outcomes when delivered in combination with the IMiD derivatives lenalidomide or pomalidomide. Here, we review these clinical data to highlight the relevance of IMiDs in combinatorial immunotherapy for both haematological and solid tumours. Further research into the molecular mechanisms of IMiDs and an increased understanding of their immunomodulatory effects may refine the specific applications of IMiDs and improve the design of future clinical trials, moving IMiDs to the forefront of combinatorial cancer immunotherapy.
摘要：
虽然免疫调节酰亚胺药物（IMiDs）已被授权用于血液癌症的治疗超过二十年，它们刺激抗肿瘤T细胞和自然杀伤（NK）细胞反应的能力的认识是相对较新的。临床试验数据越来越表明，靶向免疫疗法，如抗体，T细胞,和疫苗，与IMiD衍生物来那度胺或泊马度胺联合给药可改善结局。这里,我们回顾了这些临床数据,以强调IMiDs在血液肿瘤和实体瘤联合免疫治疗中的相关性.对IMiDs分子机制的进一步研究以及对其免疫调节作用的进一步了解可能会完善IMiDs的特定应用并改善未来临床试验的设计。将IMiD转移到组合癌症免疫疗法的最前沿。
